TN-001
TN-001 is a non-hallucinogenic psychoplastogen which is under development for the treatment of major depressive disorder and post-traumatic stress disorder (PTSD).
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
TN-001 is a non-hallucinogenic psychoplastogen which is under development for the treatment of major depressive disorder and post-traumatic stress disorder (PTSD). Its route of administration is unspecified.
The drug acts as a serotonin receptor modulator, including as a serotonin 5-HT 2A receptor partial agonist and serotonin 5-HT 2B receptor antagonist, and has been found to produce psychoplastogenic effects without inducing the head-twitch response. It is being developed by Transneural Therapeutics, a spinout of CaaMTech.
As of June 2025, TN-001 is in the preclinical research stage of development. A clinical trial is being planned. The chemical structure of the drug does not yet appear to have been disclosed.
See also
Non-hallucinogenic 5-HT 2A receptor agonist List of investigational hallucinogens and entactogens List of investigational antidepressants List of investigational post-traumatic stress disorder drugs
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372053732 under CC BY-SA 4.0; modifications have been made.